



In the Claims:

1. (canceled)
2. (original) A method of treating diseases mediated by *Mycobacterium*, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.
3. (previously presented) A method according to claim 2 wherein *Mycobacterium* is *Mycobacterium tuberculosis*.
4. (previously presented) A method according to claim 2 wherein a pleuromutilin is a compound comprising the basic structural elements as set out in formula




wherein R is vinyl or ethyl and the dotted line is a bond or is no bond.


5. (currently amended) [[Use or a]] A method according to claim 4 wherein a pleuromutilin is selected from the group consisting of
 - a compound of formula




- a compound of formula




- a compound of formula




- a compound of formula




- a compound of formula




- a compound of formula




- a compound of formula



- a compound of formula




- a compound of formula



and






- a compound of




6. (withdrawn) A compound selected from the group consisting of compounds of formulae as set out in TABLE 1:

TABLE 1

TABLE 1

	
	
<p>and</p> 	

7. (withdrawn) A compound of formula



wherein

- the dotted line is a bond (double bond between positions a=b), R_{1A} is hydrogen and R_{2A} is not present,

or

- the dotted line is no bond (single bond between positions a-b) and R_{1A} and R_{2A} independently of each other are hydrogen, halogen or deuterium,

R_{3A} is (C_{1-6}) alkyl,

R_{4A} is hydrogen, (C_{1-6}) alkyl, a group $-C(=NH)-NH_2$, or the residue of an amino acid,

R_{5A} is hydrogen, or


R_{4A} and R_{5A} together are a group $=CH-NH_2$,

R_{6A} is hydrogen or deuterium, and

m_A is 0, 1, 2, 3, 4, or 5.

8. (withdrawn) A 14-O-(oximino- (C_{3-8}) cycloalkyl-sulfanylmethylcarbonyl)-pleuromutilin and a 14-O-(hydrazono- (C_{3-8}) cycloalkyl-sulfanylmethylcarbonyl)-pleuromutilin.

9. (withdrawn) A compound of formula



wherein

R_{1B} has the meaning of R_{1A} as defined in claim 7,

R_{2B} has the meaning of R_{2A} as defined in claim 7,

R_{10B} has the meaning of R_{6A} as defined in claim 7,

the dotted line has the meaning as defined in claim 7,

m_B has the meaning of m_a as defined above,

R_{3B} is hydrogen or (C_{1-6}) alkyl,

X_B is $-O-R_{4B}$ or $-NR_{5B}R_{6B}$,

R_{4B} is hydrogen or (C_{1-6}) alkyl, optionally substituted by a group $-NR_{7B}R_{8B}$,


R_{5B} and R_{6B} independently of each other are (C_{1-4}) alkyl,

R_{7B} and R_{8B} independently of each other are (C_{1-4}) alkyl, or

R_{7B} and R_{8B} together with the nitrogen atom to which they are attached form aliphatic heterocyclyl, having 5 to 8 ring members, and

R_{9B} is hydrogen or (C_{1-4}) alkyl.

10. (withdrawn) A compound of formula



wherein

R_{1C} has the meaning of R_{1A} as defined in claim 7,


R_{2C} has the meaning of R_{2A} as defined in claim 7,

the dotted line has the meaning as defined in claim 7,

R_{4C} has the meaning of R_{6A} as defined in claim 7, and

R_{3C} is amino, (C₁₋₄)alkylamino, di(C₁₋₄)alkylamino, the residue of an amino acid, hydroxy, or (C₁₋₄)alkoxy.

11. (withdrawn) A compound of formula



wherein

R_{1D} has the meaning of R_{1A} as defined in claim 7,

R_{2D} has the meaning of R_{2A} as defined in claim 7,

R_{4D} has the meaning of R_{6A} as defined in claim 7,

the dotted line has the meaning as defined in claim 7, and

R_{3D} is aliphatic heterocyclyl of 4 to 8 ring members, and comprising one nitrogen atom as the heteroatom, or (C₄₋₈)cycloalkyl, which heterocyclyl or cycloalkyl is substituted by hydroxy or oxo.

12. (withdrawn) A compound of claim 7 in the form of a salt.

13. (withdrawn) A compound of claim 7 for use as a pharmaceutical.

14. (withdrawn) A pharmaceutical composition comprising a compound of claim 7 in association with at least one pharmaceutical excipient.

15. (withdrawn) A pharmaceutical composition according to claim 13, further comprising another pharmaceutically active agent.

16. (withdrawn) A pharmaceutical composition comprising a pleuromutilin in association with at least one pharmaceutical excipient, and further comprising another pharmaceutically active agent useful in the treatment of Mycobacterium infections.
17. (withdrawn) A compound of claim 7 for use in the preparation of a medicament for the treatment of microbial diseases.
18. (previously presented) A method of treatment of microbial diseases, which method comprises administering to a subject in need of such treatment an effective amount of a compound of claim 7.